Dyadic International, Inc. Secures $2.9 Million Through Registered Direct Offering and Concurrent Private Placement 

Rhea-AI Summary

Dyadic International (NASDAQ: DYAI) entered into definitive agreements with an institutional investor for a registered direct offering of Common Stock and a concurrent private placement of warrants, expected to generate aggregate gross proceeds of approximately $2.9 million.

The company will sell 3,625,000 Common shares at $0.795 per share and issue Common Warrants to purchase 3,625,000 shares at an exercise price of $0.84 per share, with each Warrant priced at $0.005. Closing is expected on or about August 14, 2026, subject to customary conditions. Dyadic plans to use net proceeds, along with existing cash and investment-grade securities, for general corporate purposes and working capital. Aegis Capital is acting as exclusive placement agent. The stock offering is made under an effective Form S-3 shelf registration, while the warrants are offered via a private placement to accredited investors, with related resale registration rights.

Positive

• $2.9 million expected aggregate gross proceeds to strengthen liquidity
• Issuance of 3,625,000 warrants at $0.84 exercise price provides potential future capital
• Use of proceeds targeted to general corporate purposes and working capital
• Financing supported by an institutional investor and Aegis Capital as exclusive placement agent

Negative

• Immediate dilution from issuance of 3,625,000 new Common shares
• Potential further dilution if 3,625,000 Common Warrants are exercised
• Gross proceeds of about $2.9 million indicate a relatively modest capital raise

Market Context

Historical coverage recorded 1.89% after one development agreement and -6.19% after platform news. T...

Analysis

Historical coverage recorded 1.89% after one development agreement and -6.19% after platform news. That mixed record places the financing alongside Net Selling insider activity; funding use and registration terms remain key diligence points.

Key Figures

Gross proceeds: $2.9 million Common stock offering price: $0.795 per share Warrant price: $0.005 per warrant +5 more

8 metrics

Gross proceeds $2.9 million Registered direct offering and concurrent private placement

Common stock offering price $0.795 per share Registered direct offering

Warrant price $0.005 per warrant Concurrent private placement

Shares sold 3,625,000 shares Registered direct offering

Warrants issued 3,625,000 warrants Private placement

Warrant exercise price $0.84 per share Common Warrants

Expected closing date August 14, 2026 Subject to customary closing conditions

Shelf effectiveness date August 25, 2023 Form S-3 registration statement declared effective by the SEC

Historical Context

5 past events · Latest: Aug 12 (Negative)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
Aug 12	Q2 earnings report	Negative	-15.7%	Reported continued losses, reduced liquidity, and substantial doubt about going concern
Aug 04	Development agreement	Positive	+1.9%	Expanded the non-animal dairy protein pipeline through a European biotechnology collaboration
Aug 03	Earnings date announcement	Neutral	+1.9%	Scheduled Q2 2026 financial results and a corporate update conference call
Jul 28	Platform development update	Positive	-6.2%	Reported rapid development of C1 cell lines and purified Ebola antigens
Jul 24	Listing compliance update	Positive	-1.6%	Confirmed regained compliance with Nasdaq listing requirements

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Historical reactions were mixed, with negative reactions following earnings and platform news while a development agreement produced a positive reaction.

Key Terms

registered direct offering, private placement, shelf registration statement, form s-3, +1 more

5 terms

registered direct offering financial

"purchase and sale of shares of Common Stock in a registered direct offering"

A registered direct offering is a way for a company to sell new shares of its stock directly to select investors with regulatory approval. This method allows the company to raise funds quickly and efficiently without needing a public auction, similar to offering exclusive access to a limited number of buyers. For investors, it often provides an opportunity to purchase shares at a favorable price, while giving the company immediate access to capital.

private placement financial

"with a concurrent private placement of warrants to the same investor"

A private placement is a sale of securities directly to a selected group of investors, typically institutions or accredited investors, instead of through a public offering. It lets a company raise money faster and with fewer regulatory steps; for existing shareholders it matters because the newly issued shares, often sold at a discount, increase the share count and can dilute their ownership.

shelf registration statement regulatory

"being made pursuant to an effective shelf registration statement on Form S-3"

A shelf registration statement is a document a company files with regulators that allows it to sell shares or bonds quickly when it’s a good time to raise money. It’s like having a pre-approved plan ready so the company can act fast without going through lengthy paperwork each time they want to sell, making fundraising more flexible.

form s-3 regulatory

"an effective shelf registration statement on Form S-3"

Form S-3 is a legal document companies use to register their stock sales with the government, making it easier and faster for them to raise money by selling shares to investors. It’s like having a pre-approved shopping list that lets a company quickly sell new shares when they need funds, without going through a lengthy approval process each time.

accredited investors regulatory

"The securities were offered only to accredited investors"

Accredited investors are individuals or entities considered to have enough financial knowledge and resources to understand and handle more complex and risky investments. They are often allowed to participate in private investment opportunities that are not available to the general public, similar to how experienced players might access exclusive clubs or events. This status helps ensure that investors can manage potential risks and rewards appropriately.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

JUPITER, Fla., Aug. 13, 2026 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (NASDAQ: DYAI) (the “Company”), d/b/a Dyadic Applied BioSolutions, a biotechnology company developing recombinant protein solutions across the life sciences, food and nutrition, bio-industrial and biopharmaceutical markets, today announced definitive agreements with an institutional investor for the purchase and sale of shares of Common Stock in a registered direct offering with a concurrent private placement of warrants to the same investor. Aggregate gross proceeds to the Company from both transactions are expected to be approximately $2.9 million.

The offering price per share of Common Stock is $0.795 and per Warrant is $0.005. The transactions consisted of the sale of 3,625,000 shares of Common Stock in the registered direct offering and Common Warrants to purchase 3,625,000 shares of Common Stock in the private placement with an exercise price of $0.84 per share.

Aggregate gross proceeds to the Company are expected to be approximately $2.9 million. The transactions are expected to close on or about August 14, 2026, subject to the satisfaction of customary closing conditions. The Company expects to use the net proceeds from the offerings, together with its existing cash, cash equivalents, restricted cash and investment grade securities, including accrued, for general corporate purposes and working capital.

Aegis Capital Corp. is acting as exclusive placement agent for the offerings.

The registered direct offering is being made pursuant to an effective shelf registration statement on Form S-3 (No. 333-273829) previously filed with the U.S. Securities and Exchange Commission (“SEC”) and declared effective by the SEC on August 25, 2023. A final prospectus supplement and accompanying prospectus describing the terms of the proposed offering will be filed with the SEC and will be available on the SEC’s website located at www.sec.gov. Electronic copies of the final prospectus supplement and the accompanying prospectus may be obtained, when available, by contacting Aegis Capital Corp., Attention: Syndicate Department, 1345 Avenue of the Americas, 27th floor, New York, NY 10105, by email at syndicate@aegiscap.com, or by telephone at +1 (212) 813-1010.

The offer and sale of the securities in the private placement are being made in a transaction not involving a public offering and have not been registered under the Securities Act of 1933, as amended (the “Securities Act”), or applicable state securities laws. Accordingly, the securities may not be reoffered or resold in the United States except pursuant to an effective registration statement or an applicable exemption from the registration requirements of the Securities Act and such applicable state securities laws. The securities were offered only to accredited investors. Pursuant to a registration rights agreement with the investors, the Company has agreed to file one or more registration statements with the SEC covering the resale of the Common Stock and the Shares issuable upon exercise of the pre-funded warrants and warrants.

This press release is for informational purposes only and does not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About Dyadic International, Inc.

Dyadic Applied BioSolutions is a global biotechnology company that aims to develop and commercialize scalable, non-animal protein production platforms to meet growing global demand across the life sciences, food and nutrition, and bio-industrial markets. These high-value proteins are designed to enable customers to develop more efficient, scalable and sustainable products. Dyadic’s proprietary Dapibus™ and C1 expression systems support rapid, cost-effective and flexible manufacturing.

Forward-Looking Statements

The foregoing material may contain “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, each as amended, including statements regarding the completion and timing of the registered direct offering and concurrent private placement, the satisfaction of customary closing conditions related to the registered direct offering and concurrent private placement, the proceeds that the Company expects to receive from the registered direct offering and concurrent private placement, and the intended use of proceeds from the registered direct offering and concurrent private placement. Forward-looking statements include all statements that do not relate solely to historical or current facts, including without limitation statements regarding the Company’s product development and business prospects, and can be identified by the use of words such as “may,” “will,” “expect,” “project,” “estimate,” “anticipate,” “plan,” “believe,” “potential,” “should,” “continue” or the negative versions of those words or other comparable words. Forward-looking statements are not guarantees of future actions or performance. These forward-looking statements are based on information currently available to the Company and its current plans or expectations and are subject to a number of risks and uncertainties that could significantly affect current plans. Should one or more of these risks or uncertainties materialize, or the underlying assumptions prove incorrect, actual results may differ significantly from those anticipated, believed, estimated, expected, intended, or planned. Although the Company believes that the expectations reflected in the forward-looking statements are reasonable, the Company cannot guarantee future results, performance, or achievements. Except as required by applicable law, including the security laws of the United States, the Company does not intend to update any of the forward-looking statements to conform these statements to actual results.

Ping Rawson
Chief Financial Officer
Phone: (561) 743-8333
Email: ir@dyadic.com

FAQ

What is Dyadic International's (NASDAQ: DYAI) August 2026 registered direct offering?

Dyadic International entered a registered direct offering of 3,625,000 Common shares at $0.795 per share. According to Dyadic, this is paired with a concurrent private placement of warrants, together expected to generate about $2.9 million in aggregate gross proceeds.

How much capital is Dyadic International (DYAI) raising in the August 2026 offering?

Dyadic expects to raise aggregate gross proceeds of approximately $2.9 million from the combined transactions. According to the company, this includes the sale of Common Stock and the concurrent private placement of Common Warrants to the same institutional investor.

What are the pricing terms of Dyadic International's (DYAI) August 2026 shares and warrants?

The Common Stock is priced at $0.795 per share and each Warrant at $0.005. According to Dyadic, the Common Warrants allow purchase of 3,625,000 shares of Common Stock at an exercise price of $0.84 per share.

When is Dyadic International's (DYAI) August 2026 offering expected to close?

The transactions are expected to close on or about August 14, 2026, subject to customary closing conditions. According to Dyadic, timing may depend on satisfaction of standard requirements typical for such financings.

How will Dyadic International (DYAI) use the proceeds from the August 2026 financing?

Dyadic plans to use net proceeds for general corporate purposes and working capital. According to the company, these funds will be combined with existing cash, cash equivalents, restricted cash and investment-grade securities, including accrued amounts.

Is Dyadic International's (DYAI) August 2026 warrant issuance a public or private offering?

The Common Warrants are being issued through a concurrent private placement to accredited investors. According to Dyadic, these securities are unregistered and can be resold in the United States only under an effective registration statement or a valid exemption.

What registration rights do investors receive in Dyadic International's (DYAI) August 2026 financing?

Investors receive registration rights for the resale of the Common Stock and shares issuable upon exercise of warrants. According to Dyadic, the company agreed to file one or more registration statements with the SEC covering these resales.